Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-NY108 is a gallium-68 labeled radiopharmaceutical imaging agent developed by the Affiliated Hospital of Jiangnan University for the detection and staging of prostate cancer. The agent consists of NY108, a monoclonal antibody targeting the prostate-specific membrane antigen (PSMA), which is highly expressed on the surface of prostate cancer cells. When labeled with the positron-emitting isotope gallium-68, it allows for high-resolution PET/CT imaging to identify PSMA-positive lesions. This diagnostic tool is often used in a theranostic approach to select patients for radioligand therapy with the lutetium-177 labeled counterpart, 177Lu-NY108.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 68Ga-NY108.